< Back to previous page
Researcher
Paul Declerck
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 30 Sep 2023
Projects
1 - 10 of 28
- An integrated platform for the identification, isolation and characterization of human clock antibodies.From1 Jul 2021 → TodayFunding: Department Coordination
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Anti-tau intrabodies for the treatment of Alzheimer’s diseaseFrom1 Feb 2020 → 19 Feb 2024Funding: Baekeland
- Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stage (EV-TRACE)From1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responsesFrom1 Oct 2019 → 30 Sep 2022Funding: IOF - technology validation in lab
- Development and validation of sampling and rapid assay methods for vedozilumab and ustekinumab therapeutic drug monitoringFrom1 Dec 2018 → 30 Nov 2020Funding: Foreign private sponsor - undefined
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
181 - 190 of 197
- Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes(2009)
Authors: Evelien Vandevenne, Sandy Van Buggenhout, Thomas Duvetter, Paul Declerck, Marc Hendrickx, Ann Van Loey, Ann Gils
Pages: 18 - 27 - Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor(2009)
Authors: Maarten Dewilde, Ann Gils, Paul Declerck
Pages: 69 - 75 - The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study(2009)
Authors: Ann Gils, Paul Declerck
Pages: 919 - 927 - Effect of Reteplase(trade mark) and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model(2009)
Authors: Mercedes Binda, Paul Declerck
Pages: 1018 - 1025 - The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex(2009)
Authors: Ann Gils, Paul Declerck
Pages: 7059 - 7067 - High quality structure of cleaved PAI-1-stab(2009)
Authors: Maarten Dewilde, Sergei Strelkov, Anja Rabijns, Paul Declerck
Pages: 126 - 132 - Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study(2009)
Authors: Paul Declerck
Pages: 49 - 57 - Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor(2008)
Authors: Renée Vancraenenbroeck, Marc De Maeyer, Paul Declerck, Ann Gils
Pages: 1892 - 1899 - Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody(2008)
Authors: Paul Declerck, Ann Gils
Pages: 1884 - 91 - A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state(2008)
Authors: Ann Gils, Paul Declerck
Pages: 641 - 653
Patents
1 - 1 of 1
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1